Data from 524 patients in a randomized, double-blind trial showed the antibody treatment “significantly reduced viral load” and patient medical visits,” Regeneron said.
Regeneron Releases Positive Trial Data For Covid Antibody Treatment As It Seeks Emergency FDA Authorization
